Medarex Hosts June 2nd Webcast of Ipilimumab Data Presented at ASCO
PRINCETON, N.J., May 30 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX ) is scheduled to host a webcast review of the ipilimumab data presented during the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. As previously announced, the live webcast will begin...Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab
PRINCETON, N.J., April 25 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX ) and Bristol-Myers Squibb Company (NYSE: BMY ) today announced that, after meeting with the U.S. Food and Drug Administration (FDA), the companies will delay the Biologics License Application (BLA) submission fo...Promising Therapy for Prostate Cancer
...ng surgery] asked if we were sending him samples from the same patient." ipilimumab is an antibody that appears to greatly magnify the cancer-killing action of... therapy in the same news release. The team plans more research into how ipilimumab works and how to optimize its use. More information The American Ca...Medarex Highlights Oncology Pipeline at Needham Cancer Therapeutics Conference in New York City
...rom Medarex's oncology portfolio included the following: ipilimumab is a fully human anti-CTLA-4 antibody in development for melanoma, prostate...s. Risks and uncertainties include risks associated with the development of ipilimumab and other product candidates, uncertainties related to the outcome of clini...Medarex Announces 2008 Fourth Quarter and Year End Financial Results
...ear ended December 31, 2008, decreased by $4.4 million from $20.4 million in 2007 to $16.0 million in 2008 and relates primarily to the development of ipilimumab with Bristol-Myers Squibb Company. Research and development (R&D) expenses for the year ended December 31, 2008, decreased by $3.4 millio...Medarex Reviews Recent Highlights and Outlook for 2009
...rex's continual investment in its pipeline and the net contributions to the ipilimumab program. Medarex expects its monthly cash burn rate per month for the full ...s. Risks and uncertainties include risks associated with the development of ipilimumab and other product candidates, uncertainties related to the outcome of clini...OHSU Cancer Institute finds that drug stimulated immune system in prostate cancer
...he body from immune overreactions, but when it is expressed in the presence of mutant cancer cells the result is tumor evasion of the immune response. ipilimumab is an antibody that blocks CTLA-4, releasing this safety brake, and allowing the immune response to have a stronger anti-tumor effect. ...Medarex Announces Ipilimumab Program Continues to Move Forward
Previously-Stated Guidance Remains Unchanged PRINCETON, N.J., April 3, 2008 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX ) today issued the following statement in response to the announcement by Pfizer Inc that it was discontinuing its Phase 3 clinical trial of front-li...Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
Clinical Phase I and II data presented at American Society of Clinical Oncology (ASCO) 2007 Annual Meeting CHICAGO, June 05, 2007 /PRNewswire-FirstCall/ -- Medarex, Inc. and Bristol-Myers Squibb Company today presented results from multiple clinical studies of ipilimumab (MDX-010), an investigatio...Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology
... Updated Survival Data for ipilimumab to be Presented PRINCETON, N.J., Sept. 4 /PRNews...ated patients with advanced metastatic melanoma: ipilimumab Presentations in Advanced Melanoma -- "Efficacy ...ay, September 13, 2008. -- "Clinical activity of ipilimumab in patients with advanced melanoma and brain metas...Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
...e following clinical and preclinical abstracts for ipilimumab in melanoma, prostate cancer and other cancers, as... Survival, Response, Safety and Biomarker Data of ipilimumab in Melanoma -- "Antitumor response and new lesions in advanced melanoma patients on ipilimumab treatment" (Abstract #3020, Developmental Therapeu...Medarex Announces 2009 First Quarter Financial Results
...ug conjugates, were also presented at the AACR meeting. Data from clinical trials of investigational oncology products ipilimumab (Phase 2) and MDX-1106 (Phase 1) will be presented at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) being held from May ...Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
... - Updated Survival and Biomarker Data for ipilimumab to be Presented - PRINCETON, N.J., April 29 /...ed today that the following clinical abstracts for ipilimumab in melanoma and prostate cancer, as well as for an... Survival, Response, Safety and Biomarker Data of ipilimumab in Melanoma "Association of ...BN ImmunoTherapeutics Reports Further Data on PROSTVAC(TM)
...sly reported efficacy data. Study III (Abstract no. 184) Study title: "Phase I Trial of Targeted Therapy with PSA-TRICOM Vaccine (V) and ipilimumab (ipi) in Patients (Pts) with Metastatic Castration-Resistant Prostate Cancer (mCRPC)." This NCI conducted study in patients with advanced prost...